News for WuXi Biologics (Cayman) Inc. (2269.HK)

PR NewswireHANGZHOU, China, March 3, 2025 - EffiXâ„¢ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli

- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe

WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities (MFG2 and MFG5), in Wuxi city.

PR NewswireSHANGHAI, Feb. 18, 2025 Ranked among the top 1% of more than 150,000 companies across 185 countriesTrusted by global partners for strong sustain

Ranked among the top 1% of more than 150,000 companies across 185 countries Trusted by global partners for strong sustainability commitment Recognized as a leader in Green CRDMO, driving innovation for a healthier future SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been awarded a Platinum Medal by the EcoVadis Sustainability Rating, marking the second year the company has received the rating's highest level of recognition.

PR NewswireSHANGHAI, Feb. 10, 2025 Ranked among the top 1% of companies assessed in the pharmaceutical industryRecognized as a leader in Green CRDMO, drivi

Ranked among the top 1% of companies assessed in the pharmaceutical industry Recognized as a leader in Green CRDMO, driving innovation for a healthier future Committed to creating long-term value for all stakeholders SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized as a 2025 Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics, marking the fifth consecutive year the company has scored among the highest in ESG Risk Ratings.

PR NewswireSHANGHAI and SAN DIEGO, Jan. 6, 2025 SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading glob

WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager

Named for second consecutive year named to prestigious DJSI list Leading green biologics solutions for a healthier future SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been named to the 2024 Dow Jones Sustainability Indices (DJSI), and given among the top scores for its unremitting efforts and notable achievements in promoting sustainable development.

Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO ® and $100 Million PIPE Financing

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Leading Green CRDMO Driven by Innovation for a Healthier Future Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been included in the '20 Case Examples for 20 Years: Private Sector's Sustainable Development in China' report initiated by the United Nations Global Compact. The company has been invited to UNGC global roadshow and has earned recognition for its effective and dedicated efforts to continue the advancement of green biologics solutions for a healthier future.

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line

WuXi Biologics is expected to report a more modest pace of top-line expansion and lower profit margins in fiscal 2024. See why WXIBF stock is a Hold.

Revenue increased by 1.0% YoY to RMB 8,574.2 million

Key Takeaways: U.S. sales dipped slightly, with limited impact for now from a proposed law that could limit Chinese access to the U.S. drugs market, where WuXi AppTec makes nearly two thirds of its revenue China’s drug services companies are cutting prices in a battle for business, eating into profit margins

WuXi Biologics seems to be moderating its pace of investments in the US market. Read why I have a mixed view of WXIBF stock as a potential investment.